• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Myriad Genetics Appoints Melissa Gonzales to Lead Women's Health Business

    5/20/21 7:05:00 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $MYGN alert in real time by email

    SALT LAKE CITY, May 20, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced that Melissa Gonzales has been named president of its Women's Health business.

    Gonzales has more than 20 years of women's health experience, most recently at Medela, a global leader in breast pumps and medical solutions, supporting millions of new moms and babies. She served as executive vice president of Medela Americas and helped position the company as the number one breast pump brand in the United States. Prior to Medela, Gonzales led commercial teams at Align Technology and Smith & Nephew.

    In her role at Myriad Women's Health, Gonzales will be responsible for serving consumers, patients and healthcare providers with genetic tests that help women assess their risk of hereditary cancer and provide vital insights during pregnancy or when planning a family. She will report to Nicole Lambert, president of Myriad Genetic Laboratories.

    "Melissa is a proven leader with deep relevant expertise both in partnering with healthcare systems as well as reaching patients directly. She has the passion, leadership qualities, and proven experience to accelerate the growth of our Women's Health business and elevate our products to their full potential," said Lambert. "We are fortunate to have an executive of Melissa's caliber as the most recent addition to our team."

    Myriad Women's Health offers the Myriad myRisk® Hereditary Cancer test, Myriad Foresight® Carrier Screen and Myriad Prequel™ Prenatal Screen as well as a suite of services to expand access and streamline the genetic testing process for patients and providers.

    About Myriad Genetics

    Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing for all, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit the Company's website: www.myriad.com.

    Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, EndoPredict, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

    Safe Harbor Statement

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to accelerating the growth of the Company's Women's Health business and elevating the Company's products to their full potential; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties associated with COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline or that we may not be able to operate our business on a profitable basis; risks related to our ability to generate sufficient revenue from our existing product portfolio or in launching and commercializing new tests; risks related to changes in governmental or private insurers' coverage and reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; risks related to the material weakness identified in our internal control over financial reporting, including the impact thereof and our remediation plan; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our Transition Report on Form 10-K filed with the Securities and Exchange Commission on March 16, 2021, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

    Media Contact:Jared Maxwell

    (801) 505-5027

    [email protected]
    Investor Contact:Nathan Smith

    (801) 505-5067

    [email protected]
        

     



    Primary Logo

    Get the next $MYGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MYGN

    DatePrice TargetRatingAnalyst
    5/8/2025Outperform → Peer Perform
    Wolfe Research
    5/7/2025$6.00Overweight → Equal Weight
    Wells Fargo
    4/9/2025Buy → Neutral
    Guggenheim
    3/12/2025$11.50 → $12.50Neutral → Overweight
    Piper Sandler
    2/12/2025$29.00Buy
    Craig Hallum
    12/10/2024$18.00Neutral
    UBS
    12/9/2024$30.00 → $21.00Outperform → Market Perform
    Leerink Partners
    9/19/2024$32.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $MYGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology

      SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) --  Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, announced today that JCO Precision Oncology published a real-world study suggesting that the results of RiskScore® led clinicians to recommend breast cancer screening aligned with patients' individual risk. RiskScore, Myriad's clinically validated breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test, combines a polygenic risk score (PRS) validated for all ancestries with the widely-used Tyrer-Cuzick model to predict five-year and remaining lifetime risk of breast cancer. The study, "Association of Polygenic

      5/7/25 4:30:00 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance

      Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5% year-over-year.First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®. MyRisk®testing volume in the affected population grew 11% year-over-year. First quarter 2025 gross margin of 69% increased 40 basis points year-over-year, benefiting from greater laboratory efficiencies. First quarter 2025 GAAP net loss of $0.1 million, or $0.00 EPS, driven by $29 million tax benefit. Adjusted EPS was $(0.03) in the first quarter 2025.

      5/6/25 4:05:00 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor

      SALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) -- Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective, yet concerns about potential side effects remain a significant barrier, preventing more than half (52%) from taking medication, according to the latest GeneSight® Mental Health Monitor, a nationwide survey from Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine. The majority of these patients (54%) agree that genetic testing for mental health medications (known as pharmacogenomic or PGx testing) could reduce these concerns. "It's encouraging to

      4/30/25 8:00:00 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    Financials

    Live finance-specific insights

    See more
    • Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance

      Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5% year-over-year.First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®. MyRisk®testing volume in the affected population grew 11% year-over-year. First quarter 2025 gross margin of 69% increased 40 basis points year-over-year, benefiting from greater laboratory efficiencies. First quarter 2025 GAAP net loss of $0.1 million, or $0.00 EPS, driven by $29 million tax benefit. Adjusted EPS was $(0.03) in the first quarter 2025.

      5/6/25 4:05:00 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025

      SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its first quarter 2025 earnings conference call at 4:30 pm EDT on Tuesday, May 6, 2025. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the first quarter 2025. A live webcast of the conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon register

      4/29/25 9:00:00 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025

      SALT LAKE CITY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic and genomic tumor testing and precision medicine, will hold its fourth quarter and full year 2024 earnings conference call at 4:30 pm ET on Monday, Feb. 24, 2025. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the fourth quarter and full year 2024. A live webcast of the earnings conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telep

      2/18/25 8:30:00 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Myriad Genetics Inc.

      10-Q - MYRIAD GENETICS INC (0000899923) (Filer)

      5/6/25 8:48:53 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MYRIAD GENETICS INC (0000899923) (Filer)

      5/6/25 4:08:36 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form S-8 filed by Myriad Genetics Inc.

      S-8 - MYRIAD GENETICS INC (0000899923) (Filer)

      5/1/25 4:03:06 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

      SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025. A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical technology, Donnelly has a proven track record of building and leading high-performing teams, managing multi-billion-dollar P&Ls, and driving growth through innovative go-to-market strategies. "Brian brings a unique combination of strategic vision and operational excellence, combined with a passion for patient-centric

      4/7/25 8:00:00 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics Announces Senior Leadership Transition

      SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of Directors has appointed Sam Raha, the Company's current Chief Operating Officer (COO), as President and Chief Executive Officer (CEO) and as a member of the Board, effective April 30, 2025. Mr. Raha will replace Paul J. Diaz, who is stepping down to join private equity firm Cressey & Company as a Managing Partner. Mr. Diaz will continue to serve the Company as a consultant to Mr. Raha and the Board of Directors for another year. "Since joining Myriad in December 2023, Sam has played an integral role in sh

      2/24/25 4:05:00 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Biote Announces CEO Retirement and Succession Plan

      Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

      1/30/25 4:10:00 PM ET
      $BTMD
      $HOLX
      $MYGN
      $PODD
      Medicinal Chemicals and Botanical Products
      Health Care
      Medical Electronics
      Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $MYGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Myriad Genetics Inc.

      SC 13G/A - MYRIAD GENETICS INC (0000899923) (Subject)

      11/14/24 4:16:31 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Myriad Genetics Inc.

      SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)

      5/1/24 4:21:33 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Myriad Genetics Inc.

      SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)

      4/25/24 4:18:40 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Myriad Genetics downgraded by Wolfe Research

      Wolfe Research downgraded Myriad Genetics from Outperform to Peer Perform

      5/8/25 8:27:12 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Myriad Genetics from Overweight to Equal Weight and set a new price target of $6.00

      5/7/25 8:36:31 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics downgraded by Guggenheim

      Guggenheim downgraded Myriad Genetics from Buy to Neutral

      4/9/25 8:36:07 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commerical Officer Donnelly Brian J was granted 397,534 shares (SEC Form 4)

      4 - MYRIAD GENETICS INC (0000899923) (Issuer)

      5/2/25 4:15:16 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 3 filed by new insider Donnelly Brian J

      3 - MYRIAD GENETICS INC (0000899923) (Issuer)

      5/1/25 4:29:48 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Verratti Mark

      4 - MYRIAD GENETICS INC (0000899923) (Issuer)

      5/1/25 4:27:14 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care